Opposite behavior of plasma levels surfactant protein type B and receptor for advanced glycation end products in pulmonary sarcoidosis

Damiano Magrì, Salvatore Mariotta, Cristina Banfi, Agnese Ricotta, Alessandro Onofri, Alberto Ricci, Lara Pisani, Filippo Maria Cauti, Stefania Ghilardi, Piergiuseppe Agostoni

Research output: Contribution to journalArticle

Abstract

Background No biological marker is currently available for evaluating pulmonary involvement and/or for monitoring the clinical course of sarcoidosis. The present pilot study focused on possible relationships between circulating plasma levels of surfactant protein type B (SP-B) and plasma receptor for advanced glycation end products (RAGE) and lung function abnormalities in patients with pulmonary sarcoidosis, since both SP-B and RAGE have been previously suggested as lung injury markers. The plasmatic levels of these two proteins were also investigated with respect to functional capacity, as assessed by a cardiopulmonary exercise test (CPET). Methods Thirty pulmonary sarcoidosis outpatients and fifteen volunteers (Control Group) underwent lung function tests and CPET. Resting SP-B and RAGE plasma levels were also determined. Patients were then categorized according to the severity of their pulmonary involvement, as assessed in terms of lung diffusion for carbon monoxide (DL CO) values. Results Group B showed SP-B levels higher and RAGE levels lower than Group A and Control Group (p <0.01). Group A showed lower RAGE levels than Control Group (p <0.01), whereas SP-B levels did not differ between these two groups. A significant univariate relationship was found between both SP-B and RAGE and several lung function data, particularly with DLCO (SP-B Vs DLCO: r: -0.437, p = 0.016; RAGE Vs DL CO: r: -0.451, p = 0.012). Conclusions Circulating plasma levels of SP-B and RAGE showed an opposite behavior in patients with pulmonary sarcoidosis. SP-B values are directly related to alveolar unit damage, supporting a possible role of SP-B as a marker of disease severity in these patients. Differently, RAGE decreases in severe sarcoidosis, suggesting more complex underlying mechanisms.

Original languageEnglish
Pages (from-to)1617-1624
Number of pages8
JournalRespiratory Medicine
Volume107
Issue number10
DOIs
Publication statusPublished - Oct 2013

Fingerprint

Pulmonary Sarcoidosis
Surface-Active Agents
Carbon Monoxide
Lung
Sarcoidosis
Exercise Test
Control Groups
Advanced Glycosylation End Product-Specific Receptor
IgA receptor
Respiratory Function Tests
Lung Injury
Volunteers
Outpatients
Biomarkers

Keywords

  • Cardiopulmonary exercise test
  • Lung diffusion capacity
  • Pulmonary sarcoidosis
  • RAGE
  • Surfactant protein type B

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Opposite behavior of plasma levels surfactant protein type B and receptor for advanced glycation end products in pulmonary sarcoidosis. / Magrì, Damiano; Mariotta, Salvatore; Banfi, Cristina; Ricotta, Agnese; Onofri, Alessandro; Ricci, Alberto; Pisani, Lara; Cauti, Filippo Maria; Ghilardi, Stefania; Agostoni, Piergiuseppe.

In: Respiratory Medicine, Vol. 107, No. 10, 10.2013, p. 1617-1624.

Research output: Contribution to journalArticle

Magrì, Damiano ; Mariotta, Salvatore ; Banfi, Cristina ; Ricotta, Agnese ; Onofri, Alessandro ; Ricci, Alberto ; Pisani, Lara ; Cauti, Filippo Maria ; Ghilardi, Stefania ; Agostoni, Piergiuseppe. / Opposite behavior of plasma levels surfactant protein type B and receptor for advanced glycation end products in pulmonary sarcoidosis. In: Respiratory Medicine. 2013 ; Vol. 107, No. 10. pp. 1617-1624.
@article{76ce65e358ad49c8ae0fe390947cf7b4,
title = "Opposite behavior of plasma levels surfactant protein type B and receptor for advanced glycation end products in pulmonary sarcoidosis",
abstract = "Background No biological marker is currently available for evaluating pulmonary involvement and/or for monitoring the clinical course of sarcoidosis. The present pilot study focused on possible relationships between circulating plasma levels of surfactant protein type B (SP-B) and plasma receptor for advanced glycation end products (RAGE) and lung function abnormalities in patients with pulmonary sarcoidosis, since both SP-B and RAGE have been previously suggested as lung injury markers. The plasmatic levels of these two proteins were also investigated with respect to functional capacity, as assessed by a cardiopulmonary exercise test (CPET). Methods Thirty pulmonary sarcoidosis outpatients and fifteen volunteers (Control Group) underwent lung function tests and CPET. Resting SP-B and RAGE plasma levels were also determined. Patients were then categorized according to the severity of their pulmonary involvement, as assessed in terms of lung diffusion for carbon monoxide (DL CO) values. Results Group B showed SP-B levels higher and RAGE levels lower than Group A and Control Group (p <0.01). Group A showed lower RAGE levels than Control Group (p <0.01), whereas SP-B levels did not differ between these two groups. A significant univariate relationship was found between both SP-B and RAGE and several lung function data, particularly with DLCO (SP-B Vs DLCO: r: -0.437, p = 0.016; RAGE Vs DL CO: r: -0.451, p = 0.012). Conclusions Circulating plasma levels of SP-B and RAGE showed an opposite behavior in patients with pulmonary sarcoidosis. SP-B values are directly related to alveolar unit damage, supporting a possible role of SP-B as a marker of disease severity in these patients. Differently, RAGE decreases in severe sarcoidosis, suggesting more complex underlying mechanisms.",
keywords = "Cardiopulmonary exercise test, Lung diffusion capacity, Pulmonary sarcoidosis, RAGE, Surfactant protein type B",
author = "Damiano Magr{\`i} and Salvatore Mariotta and Cristina Banfi and Agnese Ricotta and Alessandro Onofri and Alberto Ricci and Lara Pisani and Cauti, {Filippo Maria} and Stefania Ghilardi and Piergiuseppe Agostoni",
year = "2013",
month = "10",
doi = "10.1016/j.rmed.2013.07.019",
language = "English",
volume = "107",
pages = "1617--1624",
journal = "Respiratory Medicine",
issn = "0954-6111",
publisher = "W.B. Saunders Ltd",
number = "10",

}

TY - JOUR

T1 - Opposite behavior of plasma levels surfactant protein type B and receptor for advanced glycation end products in pulmonary sarcoidosis

AU - Magrì, Damiano

AU - Mariotta, Salvatore

AU - Banfi, Cristina

AU - Ricotta, Agnese

AU - Onofri, Alessandro

AU - Ricci, Alberto

AU - Pisani, Lara

AU - Cauti, Filippo Maria

AU - Ghilardi, Stefania

AU - Agostoni, Piergiuseppe

PY - 2013/10

Y1 - 2013/10

N2 - Background No biological marker is currently available for evaluating pulmonary involvement and/or for monitoring the clinical course of sarcoidosis. The present pilot study focused on possible relationships between circulating plasma levels of surfactant protein type B (SP-B) and plasma receptor for advanced glycation end products (RAGE) and lung function abnormalities in patients with pulmonary sarcoidosis, since both SP-B and RAGE have been previously suggested as lung injury markers. The plasmatic levels of these two proteins were also investigated with respect to functional capacity, as assessed by a cardiopulmonary exercise test (CPET). Methods Thirty pulmonary sarcoidosis outpatients and fifteen volunteers (Control Group) underwent lung function tests and CPET. Resting SP-B and RAGE plasma levels were also determined. Patients were then categorized according to the severity of their pulmonary involvement, as assessed in terms of lung diffusion for carbon monoxide (DL CO) values. Results Group B showed SP-B levels higher and RAGE levels lower than Group A and Control Group (p <0.01). Group A showed lower RAGE levels than Control Group (p <0.01), whereas SP-B levels did not differ between these two groups. A significant univariate relationship was found between both SP-B and RAGE and several lung function data, particularly with DLCO (SP-B Vs DLCO: r: -0.437, p = 0.016; RAGE Vs DL CO: r: -0.451, p = 0.012). Conclusions Circulating plasma levels of SP-B and RAGE showed an opposite behavior in patients with pulmonary sarcoidosis. SP-B values are directly related to alveolar unit damage, supporting a possible role of SP-B as a marker of disease severity in these patients. Differently, RAGE decreases in severe sarcoidosis, suggesting more complex underlying mechanisms.

AB - Background No biological marker is currently available for evaluating pulmonary involvement and/or for monitoring the clinical course of sarcoidosis. The present pilot study focused on possible relationships between circulating plasma levels of surfactant protein type B (SP-B) and plasma receptor for advanced glycation end products (RAGE) and lung function abnormalities in patients with pulmonary sarcoidosis, since both SP-B and RAGE have been previously suggested as lung injury markers. The plasmatic levels of these two proteins were also investigated with respect to functional capacity, as assessed by a cardiopulmonary exercise test (CPET). Methods Thirty pulmonary sarcoidosis outpatients and fifteen volunteers (Control Group) underwent lung function tests and CPET. Resting SP-B and RAGE plasma levels were also determined. Patients were then categorized according to the severity of their pulmonary involvement, as assessed in terms of lung diffusion for carbon monoxide (DL CO) values. Results Group B showed SP-B levels higher and RAGE levels lower than Group A and Control Group (p <0.01). Group A showed lower RAGE levels than Control Group (p <0.01), whereas SP-B levels did not differ between these two groups. A significant univariate relationship was found between both SP-B and RAGE and several lung function data, particularly with DLCO (SP-B Vs DLCO: r: -0.437, p = 0.016; RAGE Vs DL CO: r: -0.451, p = 0.012). Conclusions Circulating plasma levels of SP-B and RAGE showed an opposite behavior in patients with pulmonary sarcoidosis. SP-B values are directly related to alveolar unit damage, supporting a possible role of SP-B as a marker of disease severity in these patients. Differently, RAGE decreases in severe sarcoidosis, suggesting more complex underlying mechanisms.

KW - Cardiopulmonary exercise test

KW - Lung diffusion capacity

KW - Pulmonary sarcoidosis

KW - RAGE

KW - Surfactant protein type B

UR - http://www.scopus.com/inward/record.url?scp=84884817970&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884817970&partnerID=8YFLogxK

U2 - 10.1016/j.rmed.2013.07.019

DO - 10.1016/j.rmed.2013.07.019

M3 - Article

C2 - 23948664

AN - SCOPUS:84884817970

VL - 107

SP - 1617

EP - 1624

JO - Respiratory Medicine

JF - Respiratory Medicine

SN - 0954-6111

IS - 10

ER -